Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate

EU orphan designation number: EU/3/10/810   
Active ingredient: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate
Indication: Treatment of post-essential thrombocythaemia myelofibrosis
Sponsor: Sanofi-Aventis groupe
54 rue La Boétie, 75008 Paris, France

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
02/12/2010 Orphan designation EMA/OD/084/10 (2010)8595 of 26/11/2010
08/02/2011 Transfer of orphan designation EMA/OD/084/10/T/01 (2011)782 of 04/02/2011
06/11/2012 Change of name and/or address of sponsor EMA/OD/084/10